Trending

Alkem Labs signs licensing agreement with Sonnet BioTherapeutics

Image

Alkem Laboratories said that it has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, to develop, manufacture and commercialise the drug candidate 'SON-080' for the treatment of diabetic peripheral neuropathy in India.

You Might Also Like...

Sign Up for Our Newsletter

Subscribe now to get notified about exclusive offers
from The .... every week!